Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 4/20 | 0.54 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.51 |
| ▸ | F2 | P00734 | 4/20 | 0.51 |
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440671 | 0.88 | NTSR1 (0.56) | NTSR1NTSR2OPRD1 | |
| SCHEMBL30607452 | 0.82 | NTSR1 (0.47) | NTSR1NTSR2F2 | |
| SCHEMBL29845666 | 0.80 | OPRD1 (0.56) | NTSR1NTSR2OPRD1F2 | |
| SCHEMBL29440668 | 0.79 | PLK1 (0.50) | NTSR1NTSR2 | |
| SCHEMBL29551878 | 0.78 | OPRD1 (0.56) | NTSR1NTSR2OPRD1APLNRAGTR1 | |
| SCHEMBL30586481 | 0.78 | XIAP (0.53) | NTSR1NTSR2F2 | |
| SCHEMBL31461901 | 0.77 | CALCR (0.52) | — | |
| SCHEMBL31461848 | 0.77 | CALCR (0.53) | — | |
| SCHEMBL31461892 | 0.77 | CALCR (0.53) | — | |
| SCHEMBL31461927 | 0.77 | CALCRL (0.46) | NTSR1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4634193-A1 | SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12421242-B2 | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions | Karuna Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12398119-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3488837-B1 | ELECTROPORATION APPARATUS FOR PROVIDING AGENTS TO THE COCHLEA | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2024-11-27 | — | — | EP | disclosed |
| US-12144815-B2 | Use of aprepitant for treating Alzheimer's disease | HOTH THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240336619-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. | 2024-10-10 | — | — | US | disclosed |
| US-11524954-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2022-12-13 | — | — | US | disclosed |
| EP-3642202-B1 | DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2022-11-02 | — | — | EP | disclosed |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022212362-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| US-20220265672-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| CN-110944998-B | Dihydro-pyrrolo-pyridine derivatives | 辉瑞大药厂 | 2022-08-16 | — | — | CN | disclosed |
| EP-4037715-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
| CN-114630818-A | Protein-macromolecule conjugates and methods of use thereof | 北京轩义医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3766885-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-109641898-B | 5, 7-dihydro-pyrrolo-pyridine derivatives for the treatment of neurological and neurodegenerative diseases | 辉瑞公司 | 2022-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144815-B2 | Use of aprepitant for treating Alzheimer's disease | TACR1, ACHE, TACR2 | NTSR1 33/4885NTSR2 35/4885OPRD1 599/4885 |
| US-12398119-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | NTSR1 689/4885NTSR2 783/4885OPRD1 7/4885 |
| US-20220265672-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | NTSR1 33/4885NTSR2 35/4885OPRD1 599/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | NTSR1 33/4885NTSR2 35/4885OPRD1 599/4885 |
| US-20240336619-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM4, CHRM2 | NTSR1 177/4885NTSR2 150/4885OPRD1 196/4885 |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | NTSR1 799/4885NTSR2 772/4885OPRD1 1045/4885 |
| US-11524954-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | NTSR1 689/4885NTSR2 783/4885OPRD1 7/4885 |
| US-12421242-B2 | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions | CHRM3, CHRM4, CHRM2 | NTSR1 177/4885NTSR2 150/4885OPRD1 196/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | NTSR1 150/4885NTSR2 210/4885OPRD1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.